Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 22

1577P - Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response

Date

21 Oct 2023

Session

Poster session 22

Topics

Translational Research;  Immunotherapy

Tumour Site

Gastric Cancer

Presenters

Chang Gon Kim

Citation

Annals of Oncology (2023) 34 (suppl_2): S852-S886. 10.1016/S0923-7534(23)01930-0

Authors

C.G. Kim1, J. Koh2, S. Shin3, J. Shin4, M. Hong1, H.C. Chung1, S.Y. Rha1, H.S. Kim1, C. Lee1, H. Kim5, J.H. Kim6, S. Lee6, S.K. Park7, H. Kim1, S. Park8, J.Y. Ahn9, H.C. Jeung6, J.S. Lee2, Y. Nam4, M. Jung1

Author affiliations

  • 1 Division Of Medical Oncology, Department Of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 2 Graduate School Of Medical Science And Engineering,, KAIST - Korea Advanced Institute of Science and Technology, 34141 - Daejeon/KR
  • 3 Department Of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 4 Research Group Of Personalized Diet, Korea Food Research Institute, 55365 - Wanju/KR
  • 5 Department Of Pathology, Severance Hospital, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 6 Division Of Medical Oncology, Department Of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, 06273 - Seoul/KR
  • 7 Deparment Of Medical Records, Severance Hospital, Yonsei University College of Medicine, 03722 - Seoul/KR
  • 8 Songdang Institute For Cancer Research, Yonsei University College of Medicine, 120-752 - Seoul/KR
  • 9 Division Of Infectious Diseases, Department Of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, 03722 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1577P

Background

Antibiotic therapy has been known to disrupt microbiota homeostasis and systemic immune responses, both of which are linked to response to immune checkpoint blockade. We aim to investigate whether prior antibiotics (pATB) administration influences outcomes following treatment with programmed cell death protein-1 (PD-1) inhibitors or chemotherapy in patients with advanced gastric cancer (AGC).

Methods

We analysed data of patients with AGC who were treated with PD-1 inhibitors (retrospective exploratory cohort; n=152) or irinotecan (chemotherapy cohort; n=101). Patients were classified into two groups based on whether they had received pATB within 28 days prior to the treatment. Another independent retrospective validation cohort (n=123) and prospective validation cohort (n=30) treated with PD-1 inhibitors were further analysed. Distinct features in gut microbiome and circulating immune cells were analysed (experimental cohort; n=24).

Results

In the retrospective exploratory cohort, pATB administration was associated with poor 17 progression-free survival (PFS; hazard ratio [HR]=2.897, 95% confidence interval [CI]=2.043–4.109) and overall survival (OS; HR=2.294, 95% CI=1.622–3.242) but did not affect outcomes among patients treated with irinotecan. In the validation cohorts, pATB administration was associated with poor treatment outcomes following PD-1 blockade. Multivariate analysis of the overall patients treated with PD-1 inhibitors confirmed that pATB was an independent predictor of poor PFS (HR=3.243, 95% CI=2.427–4.333) and OS (HR=3.046, 95% CI= 2.358–3.935). Administration of pATB was associated with diminished gut microbiome diversity, reduced abundance of Lactobacillus gasseri, and disproportional enrichment of circulating exhaustive CD8+ T cells, all of which can hinder the efficacy of PD-1 blockade.

Conclusions

Considering the inferior treatment response and poor survival outcomes by pATB followed by PD-1 blockade, antibiotics should be prescribed with caution in patients with AGC planned to receive PD-1 inhibitors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

National Research Foundation of Korea, Ministry of Science and ICT, Yonsei University College of Medicine.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.